History

2013

Founded by Amir Jafri

January 2014

Terumo BCT, an industry-leading manufacturer of therapeutic apheresis equipment, and Immunicom enter into a strategic partnership

May 2014

Start of pre-clinical canine trial

December 2015

Completed a $5.5M Series A Preferred Stock financing

February 2016

The pre-clinical canine cancer trial ended, achieving 300 Immunopheresis treatments. Overall,  50-60%  of  the  canine patients  treated  were  observed  to  have  either a stable  disease or partial response. One canine experienced  a  complete  response  with  clearance  of  metastases.

December 2017

University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology

May 2018

The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer

August 2018

Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic

June 2019

First patient enrolled in a multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis as a treatment for patients with triple negative breast cancer

July 2019

Immunicom hosted the First Annual Global Immunopheresis Conference in Krakow, Poland

July 2020

First patient enrolled in a clinical trial at Sheba Medical Center to investigate the outcomes of ImmunopheresisTM as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, triple negative breast cancer, renal cell carcinoma and non-small cell lung cancer

March 2021

The ImmunopheresisTM LW-02 column received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC)

Get in touch today

Let’s talk about what we can achieve together

Learn more about
our team